Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Short-term Investments (2020 - 2023)

Ascendis Pharma A's Short-term Investments history spans 4 years, with the latest figure at $7.8 million for Q4 2023.

  • For Q4 2023, Short-term Investments fell 97.36% year-over-year to $7.8 million; the TTM value through Dec 2023 reached $7.8 million, down 97.36%, while the annual FY2023 figure was $7.9 million, 97.43% down from the prior year.
  • Short-term Investments for Q4 2023 was $7.8 million at Ascendis Pharma A, down from $296.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $296.6 million in Q4 2022 and bottomed at $7.8 million in Q4 2023.
  • The 4-year median for Short-term Investments is $214.9 million (2020), against an average of $183.6 million.
  • The largest annual shift saw Short-term Investments soared 68.49% in 2021 before it plummeted 97.36% in 2023.
  • A 4-year view of Short-term Investments shows it stood at $160.1 million in 2020, then skyrocketed by 68.49% to $269.7 million in 2021, then rose by 9.95% to $296.6 million in 2022, then tumbled by 97.36% to $7.8 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Short-term Investments are $7.8 million (Q4 2023), $296.6 million (Q4 2022), and $269.7 million (Q4 2021).